[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"telogen-effluvium\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:telogen-effluvium":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100565951","phase-2-clinical-study-of-da-001-as-a-treatment-for-hair-shedding-reduction-and-hair-re-growth-100565951",false,"NCT06648850","Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with telogen effluvium\n* Willing and able to apply the treatment as directed, comply with study\n* Otherwise healthy\n* Able to give informed consent\n\nExclusion Criteria:\n\n* A medical history that may interfere with study objectives\n* Women who are pregnant, lactating, or planning to become pregnant during the study period\n* Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)\n* Subjects who have known allergies to any excipient in DA-001\n* Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation\n* Subject is unable to provide consent or make the allotted clinical visits","ALL","18 Years",{"count":18,"type":19},1120,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE2","PHASE3","The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth",[26,27,28,29,30,31],"Telogen Effluvium","Female Pattern Hair Loss","Female Pattern Hair Loss, Androgenic Alopecia","Male Pattern Baldness","Androgenetic Alopecia","Androgenetic Alopecia (AGA)",[33,34],"Hair Shedding","hair growth","NOT_YET_RECRUITING","2026-04-08",{"date":38,"type":39},"2026-04-13","ACTUAL",{"date":41,"type":19},"2026-05-01",{"date":43,"type":19},"2027-04-26",{"name":45,"class":46},"Applied Biology, Inc.","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100630160","efficacy-and-safety-of-a-drinkable-nutraceutical-for-hair-loss-in-patients-using-glp-1gip-receptor-agonists-100630160","NCT07484061","Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1\u002FGIP Receptor Agonists","Evaluation of the Efficacy and Safety of a Drinkable Nutraceutical in Improving Hair Loss in Patients Treated With GLP-1\u002FGIP Receptor Agonists: a Double-blind, 1:1 Randomized, Placebo-controlled Study.","Inclusion Criteria:\n\n* Female gender.\n* Age \\>35 years.\n* Initiation of treatment with a GLP-1\u002FGIP agonist, or treatment duration \\\u003C 3 months, as per routine clinical practice in the endocrinology clinic.\n* Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.\n* Additional criteria to be included by the client.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.\n* Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.\n* Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).\n* Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.\n* Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.\n* Women who have used anti-hair loss products within the last 3 months.\n* Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.).\n* Women who have undergone hair transplantation within the 18 months prior to study initiation.\n* Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months.\n* Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation.\n* Pregnant women, postpartum women (within 6 months), breastfeeding women, or women planning to become pregnant during the study period.\n* Additional exclusion criteria to be specified by the sponsor.\n* Any condition that, in the investigator's opinion, makes participation in the study inappropriate.","FEMALE","35 Years",{"count":57,"type":19},40,[59],"NA","The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1\u002FGIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.",[26],"RECRUITING","2026-03-19",{"date":65,"type":39},"2026-03-23",{"date":67,"type":39},"2026-03-16",{"date":69,"type":19},"2026-10-31",{"name":71,"class":46},"Olistic Research Labs S.L.",1]